Schering Claritin Awaits FDA Certification; Correctol SKUs To Be Discontinued
This article was originally published in The Tan Sheet
Schering-Plough's first batch of products submitted to FDA for certification under a May 16 consent decree will include the Claritin 10 mg dose
You may also be interested in...
GlaxoSmithKline appears to have negotiated a more favorable consent decree agreement with FDA compared to previous pharmaceutical companies facing similar action
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities